Biopharma Companies to Watch This Week

By Chris Lange Updated Mar 13, 4:46PM EDT · Published Jul 1, 8:20AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Biopharma Companies to Watch This Week — © shironosov / iStock

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).

Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and for the month of July.

Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.52, with a consensus analyst target price of $84.66 and a 52-week trading range of $25.50 to $76.29.

Epizyme Inc. (NASDAQ: EPZM) is expected to issue an update on its partial clinical hold of tazemetostat following reports of a child with advanced poorly differentiated chordoma, a rare bone cancer, developing a secondary T-cell lymphoma. Trial enrollment outside the United States has not been affected. Shares of Epizyme closed Friday at $13.55, in a 52-week range of $11.15 to $21.40 and with a consensus analyst target of $25.25.

[nativounit]

Omeros Corp. (NASDAQ: OMER) is expected to release data from its Phase 2 study of OMS721/IgAN in patients not taking steroids (U.S. cohort). Shares of Omeros closed Friday at $18.14. The consensus analyst target is $36.40, and the 52-week range is $8.36 to $25.20.

Tesaro Inc. (NASDAQ: TSRO) is expected to issue an update on its regulatory discussions with FDA regarding niraparib in breast cancer. Shares of Omeros closed Friday at $44.47, with a consensus analyst target of $77.67 and a 52-week range of $38.40 to $143.45.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

[recirclink id=474237]

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.